Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocean Biomedical

0.0622
-0.0047-7.03%
Post-market: 0.06410.0019+3.05%19:58 EDT
Volume:21.29M
Turnover:1.33M
Market Cap:8.21M
PE:-0.06
High:0.0695
Open:0.0695
Low:0.0561
Close:0.0669
Loading ...

Ocean Biomedical Inc - Michelle Berrey to Act as Interim Chief Executive Officer

THOMSON REUTERS
·
30 Oct 2024

Ocean Biomedical Inc - Elizabeth Ng to Take a Sabbatical for Personal Reason

THOMSON REUTERS
·
30 Oct 2024

BRIEF-Ocean Biomedical receives Nasdaq staff determination letter

Reuters
·
23 Oct 2024

Ocean Biomedical receives noncompliance letter from Nasdaq

TIPRANKS
·
23 Oct 2024

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

THOMSON REUTERS
·
23 Oct 2024

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

GlobeNewswire
·
23 Oct 2024

BRIEF-Ocean Biomedical- Ratified Fully Countersigned Copy Of Revised Agreement With Virion Therapeutics Received On Sept 26

Reuters
·
18 Oct 2024

Ocean Biomedical- Ratified Fully Countersigned Copy of Revised Agreement With Virion Therapeutics Received on Sept 26

THOMSON REUTERS
·
18 Oct 2024

Ocean Biomedical- Ownership in Virion to Equal 22% of Virion's Issued & Outstanding Membership Interests, in Exchange for $9 Mln

THOMSON REUTERS
·
18 Oct 2024

BRIEF-Molecure (Wse Moc) And Nasdaq-Listed Biotechnology Company Ocean Biomedical (Nasdaq Ocea) Sign An Exclusive Licensing Agreement For The Development And Commercialization Of Selective Ykl-40 Inhibitors

Reuters
·
15 Oct 2024

Ocean Biomedical, Molecure sign licensing agreement for YKL-40 inhibitors

TIPRANKS
·
15 Oct 2024

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

GlobeNewswire
·
01 Oct 2024